- Trials with a EudraCT protocol (25)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
25 result(s) found for: exercise and diet intervention.
Displaying page 1 of 2.
| EudraCT Number: 2020-001069-35 | Sponsor Protocol Number: IIBSP-EDA-2020-18 | Start Date*: 2021-07-06 |
| Sponsor Name:Institut de Recerca de l’Hospital de la Santa Creu i Sant Pau – IIB Sant Pau | ||
| Full Title: Impact of Exercise and Mediterranean diet vs Aspirin on live-birth rate and cardiovascular programming in In Vitro Fertilization (MEDITATE-IVF): a Randomized Study. | ||
| Medical condition: Cumulative live-birth rate. | ||
| Disease: | ||
| Population Age: Adults | Gender: Female | |
| Trial protocol: ES (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2010-022897-14 | Sponsor Protocol Number: PreMENAC-2011-01 | Start Date*: 2011-05-02 |
| Sponsor Name:Dep. of Cancer Research and Molecular medicine, Norwegian University of Science and Technology | ||
| Full Title: PreMENAC: Multimodal Exercise/Nutrition/Anti-inflammatory treatment for Cachexia: A feasibility study (phase II) | ||
| Medical condition: Diagnosis of non operable non-small cell lung cancer NSCLC (stage III-IV) or pancreatic cancer | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: NO (Completed) GB (Completed) DK (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2005-001670-27 | Sponsor Protocol Number: CSO1 | Start Date*: 2005-11-14 |
| Sponsor Name:Greater Glasgow NHS Health Board / University of Glasgow co-sponsorship | ||
| Full Title: Reversibility of cerebrovascular endothelial dysfunction in diabetes: the role of allopurinol. | ||
| Medical condition: Type Two Diabetes Mellitus | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male | |
| Trial protocol: GB (Prematurely Ended) | ||
| Trial results: View results | ||
| EudraCT Number: 2005-004848-31 | Sponsor Protocol Number: P04039 | Start Date*: 2006-01-31 | |||||||||||
| Sponsor Name:SCHERING-PLOUGH | |||||||||||||
| Full Title: A Multicenter, Randomized, Parallel-Groups, Double-Blind Placebo Controlled Study Comparing The Efficacy, Safety, And Tolerability Of Administration Of Ezetimibe/Simvastatin tablet 10/20 Mg Versus ... | |||||||||||||
| Medical condition: Hypercholesterolemia | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2013-004830-14 | Sponsor Protocol Number: UX007-CL201 | Start Date*: 2014-02-26 |
| Sponsor Name:Ultragenyx Pharmaceutical Inc. | ||
| Full Title: An Open-Label Phase 2 Study to Assess Safety and Clinical Effects of UX007 in Subjects with Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD) | ||
| Medical condition: Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD) | ||
| Disease: | ||
| Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
| Trial protocol: GB (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2019-003772-39 | Sponsor Protocol Number: DEMAND-pilot | Start Date*: 2019-12-13 |
| Sponsor Name:Umeå University | ||
| Full Title: Diet, physical exercise, and metabolic control intervention to reduce the incidence of major neurocognitive disorders among individuals with type 2 diabetes combined with mild neurocognitive impair... | ||
| Medical condition: Type 2 diabetes | ||
| Disease: | ||
| Population Age: Elderly | Gender: Male, Female | |
| Trial protocol: SE (Ongoing) | ||
| Trial results: View results | ||
| EudraCT Number: 2009-016178-33 | Sponsor Protocol Number: 1245.25 | Start Date*: 2010-11-12 | |||||||||||
| Sponsor Name:Boehringer Ingelheim B.V. | |||||||||||||
| Full Title: A Phase III, multicentre, international, randomised, parallel group, double blind cardiovascular safety study of BI 10773 (10 mg and 25 mg administered orally once daily) compared to usual care in ... | |||||||||||||
| Medical condition: The study will be performed in patients with type 2 diabetes mellitus and high cardiovascular risk who have insufficient glycaemic control despite diet and exercise and are either treatment naïve o... | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: NL (Completed) DK (Completed) ES (Completed) BE (Completed) FR (Completed) IT (Completed) HU (Completed) PT (Completed) GB (Completed) AT (Completed) GR (Completed) PL (Completed) EE (Completed) CZ (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2022-002470-86 | Sponsor Protocol Number: 20190218 | Start Date*: 2023-05-08 | ||||||||||||||||
| Sponsor Name:Amgen Inc. | ||||||||||||||||||
| Full Title: A Phase 2 Randomized, Placebo-controlled, Double-blind, Dose-ranging Study to Evaluate the Efficacy, Safety and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without... | ||||||||||||||||||
| Medical condition: Overweight and Obesity | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: DE (Trial now transitioned) HU (Trial now transitioned) CZ (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2011-003810-18 | Sponsor Protocol Number: H9X-MC-GBDE | Start Date*: 2012-07-11 | |||||||||||
| Sponsor Name:Eli Lilly & Company | |||||||||||||
| Full Title: A Randomized, Open-Label, Parallel-Arm Study Comparing the Effect of Once-Weekly Dulaglutide with Once-Daily Liraglutide in Patients with Type 2 Diabetes (AWARD-6: Assessment of Weekly AdministRati... | |||||||||||||
| Medical condition: Diabetes Mellitus, Type 2 | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: CZ (Completed) HU (Completed) DE (Completed) PL (Completed) ES (Completed) SK (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2008-006020-53 | Sponsor Protocol Number: MIPO3500108 | Start Date*: 2009-04-08 | |||||||||||
| Sponsor Name:Genzyme Europe B.V. | |||||||||||||
| Full Title: A Prospective Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Mipomersen in Patients With Severe Hypercholesterolemia on a Maximally Tolerated Lipid-Lowering... | |||||||||||||
| Medical condition: Patients With Severe Hypercholesterolemia on a Maximally Tolerated Lipid-Lowering Regimen and Who are Not on Apheresis | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) CZ (Completed) GB (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2012-001390-88 | Sponsor Protocol Number: NT13034 | Start Date*: 2012-06-05 |
| Sponsor Name:Institute for Clinical and Experimental Medicine | ||
| Full Title: Cardioprotective and metabolic effects of metformin in patients with heart failure and diabetes | ||
| Medical condition: type 2 diabetes mellitus, heart failure | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: CZ (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2021-002803-37 | Sponsor Protocol Number: XC001-1001 | Start Date*: 2022-01-20 | |||||||||||
| Sponsor Name:XyloCor Therapeutics, Inc. | |||||||||||||
| Full Title: A Phase 1/2 Trial of Direct Administration of AdVEGF-All6A+, a Replication Deficient Adenovirus Vector Expressing a cDNA/Genomic Hybrid of Human Vascular Endothelial Growth Factor, to the Ischemic ... | |||||||||||||
| Medical condition: Angina Pectoris Secondary | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: PL (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2021-000994-96 | Sponsor Protocol Number: 214725 | Start Date*: 2021-07-14 |
| Sponsor Name:GlaxoSmithKline Biologicals | ||
| Full Title: A Phase III, double-blind, randomized, placebo-controlled study to evaluate the safety, reactogenicity and immune response of a single intramuscular dose of unadjuvanted RSV Maternal vaccine, in hi... | ||
| Medical condition: High risk pregnant women (prevention of RSV-associated lower respiratory tract illnesses (LRTIs) in infants) | ||
| Disease: | ||
| Population Age: Adolescents, Under 18, Adults | Gender: Female | |
| Trial protocol: FI (Completed) ES (Temporarily Halted) IT (Completed) Outside EU/EEA | ||
| Trial results: View results | ||
| EudraCT Number: 2021-001081-38 | Sponsor Protocol Number: ARCT-810-03 | Start Date*: 2021-12-23 | |||||||||||
| Sponsor Name:Arcturus Therapeutics, Inc. | |||||||||||||
| Full Title: Phase 2, Randomized, Double-Blind, Placebo-Controlled, Nested Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ARCT-810 in Adolescent and Adult ... | |||||||||||||
| Medical condition: Ornithine transcarbamylase deficiency | |||||||||||||
|
|||||||||||||
| Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: BE (Completed) ES (Completed) FR (Completed) SE (Completed) IT (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2020-004774-22 | Sponsor Protocol Number: GIP-SEMA | Start Date*: 2021-07-08 | ||||||||||||||||
| Sponsor Name:Herlev Gentofte Hospital | ||||||||||||||||||
| Full Title: The separate and combined effects of long-term GIP and GLP-1 receptor activation in patients with type 2 diabetes | ||||||||||||||||||
| Medical condition: Type 2 diabetes mellitus | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: DK (Completed) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2011-001538-41 | Sponsor Protocol Number: | Start Date*: 2011-06-29 | |||||||||||
| Sponsor Name:University of Birmingham | |||||||||||||
| Full Title: The impact of the combination of the GLP-1 analogue liraglutide (Victoza) and laparoscopic adjustable gastric banding (LAGB) on diabetes control | |||||||||||||
| Medical condition: This trial will investigate the effects of the study treatment arms (gastric band + placebo; gastric band + liraglutide) on diabetes resolution in obese patients. | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2012-002911-24 | Sponsor Protocol Number: H9X-MC-GBDG | Start Date*: 2013-04-19 | |||||||||||
| Sponsor Name:Eli Lilly and Company | |||||||||||||
| Full Title: Protocol H9X-MC-GBDG A Randomized, Parallel-Arm, Double-Blinded Study Comparing the Effect of Once-Weekly Dulaglutide with Placebo in Patients with Type 2 Diabetes Mellitus on Sulfonylurea Therapy... | |||||||||||||
| Medical condition: Diabetes Mellitus, Type 2 | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: AT (Completed) SI (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2021-003612-31 | Sponsor Protocol Number: I8F-MC-GPGV | Start Date*: 2022-08-16 |
| Sponsor Name:ELI LILLY & COMPANY, LILLY CORPORATE CENTER | ||
| Full Title: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study with an Open-Label Extension Assessing the Efficacy, Safety, and Pharmacokinetics/Pharmacodynamics of Tirzepatide in Pediatric and Adol... | ||
| Medical condition: Type 2 Diabetes Mellitus (T2DM) | ||
| Disease: | ||
| Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
| Trial protocol: IT (Completed) FR (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2022-003205-29 | Sponsor Protocol Number: CAP2022-1 | Start Date*: 2023-02-23 | |||||||||||
| Sponsor Name:Aphaia Pharma US LLC | |||||||||||||
| Full Title: A Phase II, randomized, placebo – controlled crossover proof-of-concept study to evaluate efficacy and safety of distal jejunal-release dextrose beads formulation (APHD-012) in subjects with a path... | |||||||||||||
| Medical condition: Subjects with a pathological Oral Glucose Tolerance Test (OGTT) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: SK (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2004-004090-29 | Sponsor Protocol Number: AVD100521 | Start Date*: 2005-02-07 | |||||||||||
| Sponsor Name:GlaxoSmithKline Research & Development Ltd [...] | |||||||||||||
| Full Title: A Phase III, 18 Month, Multicenter, Randomized, Double-Blind, Active-Controlled Clinical Trial to Compare Rosiglitazone versus Glipizide on the Progression of Atherosclerosis in Subjects with Type ... | |||||||||||||
| Medical condition: atherosclerosis in Type 2 Diabetes Mellitus patients with cardiovascular disease | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: SE (Completed) DE (Completed) LV (Completed) IT (Completed) CZ (Completed) GR (Completed) ES (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.